Multinationals may lose some of their access to Russia's vaccines market thanks to pressure from state corporation Rosteh, with 11 billion rubles ($300 million) in state contracts at stake.
Having backed biotech IT businesses like Comprehend Systems and SV Bio in the U.S., high-profile venture firm Sequoia Capital has turned its attention to India. And with a $530 million fund to fuel its ambitions, the California-based VC shop could kick-start the tech and healthcare startup ecosystem in India and across Southeast Asia.
Having seen off Roche's 454 Life Sciences and established a big lead over its remaining rivals, Illumina now faces a new challenger for the DNA sequencing market.
After winning approval in Canada for its ultrasound technology designed to destroy uterine fibroids, Israel's InSightec is now headed to China with with its ExAblate device.
GlaxoSmithKline's emerging-market vaccines sales have seen better days, thanks to a $489 million bribery probe that recently led to the indictment of the company's former China head. But according to a local exec, good times are ahead for Glaxo's vaccines unit in India--and the company's recent pickup of Novartis' non-flu vaccine assets will help it get there.
Ever since China began investigating GlaxoSmithKline's business practices last year, analysts have feared the British drug giant could get in big trouble in its home country, too. Their worries appear to be justified as Britain's Serious Fraud Office said today it had opened a criminal investigation.
The Chinese government approved a joint venture between Italian cardiac device giant Sorin and MicroPort Scientific, paving the way for the new company to grab a share of the country's growing healthcare market.
Not satisfied with being the world's biggest health-care products company, Johnson & Johnson will expand its already dominant presence in China later this year when it introduces plates and screws manufactured in the country at its Suzhou facility.
Jubilant will use some of the cash to improve its generic drug manufacturing plants in India while also tapping the bank's emerging market healthcare expertise.
Michael Orsinger, chairman of Johnson & Johnson's DePuy Synthes orthopedics unit, said May 22 that customers are demanding a "one stop shop" approach toward implants, predicting that it will drive continued consolidation in the industry.